ANDREA-LD; Anti-psychotic drug reduction in primary care for adults with Learning disabilities

Phase 1

• Conditions: Aggression and challenging behaviour in adults with learning disabilities; Therapeutic area: Psychiatry and Psychology [F] - Behaviours [F01]

• Registration Number: EUCTR2013-000389-12-GB
• Lead Sponsor: Cardiff University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-07-29
• Study Completion: 2016-06-30
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 22

Inclusion Criteria

Participants will be: i. Adult (18 years or over). ii. Have a learning disability as judged by administrative classification (e.g. on practice learning disability register, in receipt of an annual learning disability health check, in receipt of learning disability services) and a score on the Adaptive Behaviour Scale that converts to an estimated IQ of 70 or below using the method described by Moss and Hogg (1997). iii. Currently prescribed one of two anti-psychotic drugs, haloperidol or risperidone, for treatment of challenging behaviour.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 310
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

Other than the obverse of the inclusion criteria, participants will be excluded if: i. They have a current diagnosis of psychosis, ii. They have had a known recurrence of psychosis following previous drug reduction in the past 3 years, iii. The clinician responsible for their treatment judges for any other reason that the participation in a drug reduction programme may be counter-indicated.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified